Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
Status:
Completed
Trial end date:
2018-05-29
Target enrollment:
Participant gender:
Summary
This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to
evaluate the effect of severe renal impairment (RI) on the safety, tolerability,
pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to
demographically-matched healthy participants with normal renal function.